The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease

European Journal of Endocrinology

Volumn 157, Issue 4, 2007, Pages 393-398

  Giordano, R ^a   Picu, A ^a   Bonelli, L ^a   Broglio, F ^a   Prodam, F ^a   Grottoli, S ^a   Muccioli, G ^b   Ghigo, E ^a   Arvat, Emanuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTISTATIN 17; GLUCOSE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; NEUROPEPTIDE; SODIUM CHLORIDE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CUSHING DISEASE; DIET RESTRICTION; FEMALE; HORMONE INHIBITION; HUMAN; HYPOPHYSIS ADENOMA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING; RECEPTOR UPREGULATION; TRANSSPHENOIDAL HYPOPHYSECTOMY;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; CARRIER PROTEINS; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN; MALE; MIDDLE AGED; NEUROPEPTIDES; PITUITARY ACTH HYPERSECRETION; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 35549010235     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0147     Document Type: Article

References (30)

1. Brown MR, Rivier C & Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 1984 114 1546-1549.
2. Stafford PJ, Kopelman PG, Davidson K, McLoughlin L, White A, Ress LH, Besser GM, Coy DH & Grossman A. The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clinical Endocrinology 1989 30 661-666.
3. Volpi R, Chiodera. P, Capretti L, Caiazza A, Caffari G, Magotti MG, Boni S & Coiro V. Inhibition by somatostatin of the growth hormone, but not corticotropin response to angiotensin II in normal men. Hormone Research 1996 45 269-272.
4. Lamberts SWJ, Krenning EP & Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 1991 12 450-481.
5. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J & Muller OA. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. European Journal of Endocrinology 1994 130 125-131.
6. Ambrosi B, Bochicchio D, Fadin C, Colombo P & Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. Journal of Endocrinological Investigation 1990 13 257-261.
7. Lamberts SW, van der Lely AJ & Hofland LJ. New somatostatin analogs: will they fulfil old promises? European Journal of Endocrinology 2002 146 701-705.
8. Lamberts SW, Uitterlinden P & Klijn JM. The effect of long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinologica 1989 120 760-766.
9. Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S & Pfeiffer EF. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klinische Wochenschrift 1976 54 173-175.
10. Tyrrell JB, Lorenzi M, Gerich JE & Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 1975 40 1125-1127.
11. 2+ levels by somatostatin in human corticotropin-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1990 70 1262-1268.
12. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW & Holland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTR release by corticotroph tumor cells. American Journal of Physiology. Endocrinology and Metabolism 2005 289 E278-E287.
13. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A & Lamberts SW. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 2005 152 645-654.
14. Arnaldi G, Polenta M, Cardinaletti M & Boscaro M. Potential indications for somatostatin analogs in Cushing's syndrome. Journal of Endocrinological Investigation 2005 28 106-110.
15. de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CL, Siggins GR, Henriksen SJ & Sutcliffe JG. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 1996 381 242-245.
16. de Lecea L. Cortistatin: a natural somatostatin analog. Journal of Endocrinological Investigation 2005 28 (Supp) 10-14.
17. Fukusumi S, Kitada C, Takekawa S, Kizawa H, Sakamoto J, Miyamoto M, Hinuma S, Kitano K & Fujino M. Identification and characterization of a novel human cortistatin-like peptide. Biochemical and Biophysical Research Communications 1997 232 157-163.
18. Broglio F, Arvat E, Benso A, Gottero C, Prodam F, Grottoli S, Papotti M, Muccioli G, van der Lely AJ, Deghenghi R & Ghigo E. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 3783-3790.
19. Gottero C, Prodam F, Destefanis S, Benso A, Gauna C, Me E, Filtri L, Riganti F, Van Der Lely AJ, Chigo E & Broglio F. Cortistatin-17 and-14 exert the same endocrine activities as somatostatin in humans. Growth Hormone and IGF Research 2004 14 382-387.
20. Grottoli S, Gasco V, Broglio, F, Baldelli R, Ragazzoni F, Gallenca F, Mainolfi A, Prodam F, Muccioli G & Ghigo E. Cortistatin-17 and somatostatin-14 display the same effects on GH, PRL and insulin secretion in patients with acromegaly or prolactinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 1595-1599.
21. Spier AD & de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Research Reviews 2000 33 228-241.
22. Robas N, Mead E & Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. Journal of Biological Chemistry 2003 278 44400-44404.
23. Allia E, Taraba E, Volante M, Cerrato M, Ghigo E, Muccioli G & Papotti M. Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuro-endocrine tissues and related tumours. Journal of Pathology 2005 207 336-345.
24. Deghenghi R, Papotti M, Ghigo E & Muccioli G. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. Journal of Endocrinological Investigation 2001 24 RC1-RC3.
25. van der Lely AJ, Tschop M, Heiman ML & Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine Reviews 2004 25 426-457.
26. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 27 S5-S10.
27. Nelder JA. A user's guide to the evaluation of statistical packages and systems. International Statistical Review 1974 42 291-298.
28. Lamberts SW, Zuyderwijk J, Den Holder F, Van Koetsveld P & Hofland L. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989 50 44-50.
29. Magiakou MA, Mastorakos G, Gomez MT, Rose SR & Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. Journal of Clinical Endocrinology and Metabolism 1994 78 131-137.
30. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD & Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. Journal of Clinical Endocrinology and Metabolism 1994 78 1312-1319.